<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity </plain></SENT>
<SENT sid="1" pm="."><plain>In this <z:hpo ids='HP_0001909'>leukemia</z:hpo> phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL), or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Irofulven was given as an intravenous infusion over five minutes daily for five days </plain></SENT>
<SENT sid="3" pm="."><plain>The starting dose was 10 mg/m2/day (50 mg/m2/course) </plain></SENT>
<SENT sid="4" pm="."><plain>Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty patients [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>: 17 patients; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: one patient; ALL: one patient; mixed lineage <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>: one patient] were treated </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002018'>Nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, hepatic dysfunction, <z:mp ids='MP_0000746'>weakness</z:mp>, <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo>, and <z:hpo ids='HP_0100598'>pulmonary edema</z:hpo> were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day </plain></SENT>
<SENT sid="7" pm="."><plain>The MTD was defined as 10 mg/m2/day for five days </plain></SENT>
<SENT sid="8" pm="."><plain>One patient with primary resistant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> achieved complete remission </plain></SENT>
<SENT sid="9" pm="."><plain>Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and in other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors </plain></SENT>
</text></document>